Convatec (LSE:CTEC) has given shareholders two signals of confidence this year: a 15% increase in its Interim Dividend and a $200m share buyback. Yet the group's trailing Payout Ratio sits above 100%, which makes the income story more nuanced than the headline rise suggests. The figures below come from a data snapshot dated 7 October 2026, alongside the most recent company news.

The dividend in numbers

The snapshot shows an annual dividend of 5.37p per share, with the latest interim payment at 1.61p. That produces a trailing 12-month Yield of 2.6%, and the indicated yield is also 2.6%, so the forward-looking measure gives the same picture as the backward-looking one. Year-on-year dividend growth stands at 6.2%.

Convatec has paid dividends for nine consecutive years and has raised them for the past two. That is a respectable record for a Business of its age on the stock market, but it is far shorter than the multi-decade streaks found among the index's older income names. The two-year growth run also suggests the progressive pattern is relatively young and still has to prove itself through a full cycle.

The company reports in US dollars, so the sterling figures in the data can also move with exchange rates, and UK investors should bear that in mind when comparing one payment with another.

Reading a payout above 100%

The most striking number is the trailing payout ratio of 121.1%. Taken at face value, it means dividends exceeded Earnings Per Share over the period measured, leaving cover of roughly 0.8 times. A sustained reading at that level would usually be a warning sign, because a company cannot indefinitely distribute more than it earns without relying on cash reserves or borrowing.

There is context, however. Convatec's first-half results, published in August, included a $69m non-cash Impairment linked to US reimbursement changes affecting its InnovaMatrix product. Non-cash charges of that kind reduce reported earnings without draining cash in the period, and they can inflate a payout ratio calculated on statutory profit. It is hard to say precisely how much of the 121.1% is attributable to that charge, but it is a reason not to treat the ratio in isolation. Management's guidance for cash conversion of around 100% is the more relevant test of whether the dividend is being funded comfortably.

Trading behind the payout

In the first half, Revenue rose 4.4% to $1,232m, or 5.0% organically excluding InnovaMatrix. Adjusted operating profit climbed 3.9% to $262m and adjusted Diluted Earnings per Share grew 6.3%. Growth came from across its chronic care categories, supported by new products and Demand in infusion care.

InnovaMatrix has been the persistent complication. In May, the shares fell almost 6% in early trading, to around 201.6p, after a trading update showed organic growth of just 1.6% when the product was included, even though growth excluding it was a healthier 4.8%. Investors also appeared wary of growth being weighted towards the second half.

What to watch

The company's 2026 targets call for mid-single-digit organic revenue growth, an adjusted Operating Margin of at least 23% and double-digit growth in adjusted earnings per share. Further out, it is aiming for revenue growth of 6% to 8% a year from 2027 and margins in the mid-20s.

Income investors should watch completion of the $200m buyback, which is due by the year end, and whether the final dividend sustains the momentum of the 15% interim rise. Last year Convatec (LSE:CTEC) published an update covering the ten months to the end of October, so a similar statement would be a natural next data point. Above all, a falling payout ratio would show earnings catching up with distributions.